June 13, 2025-- M31 Technology Corporation (M31) has once again been ranked in the top 5% of listed companies in the Corporate Governance Evaluation, marking four consecutive years among the top ...

If you buy something via one of our links, we may earn a commission. While there were some changes to the narrower skis in the ARV/ARW lineups, the ARV 116 JJ returned for 2023-24 unchanged. I’ve ...

Company to showcase preclinical studies of ARV-393, an investigational oral PROTAC BCL6 degrader, as a single agent in models of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type ...

Company to showcase preclinical studies of ARV-393, an investigational oral PROTAC BCL6 degrader, as a single agent in models of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type (AITL) ...

Hsinchu, Taiwan - October 2nd, 2018 - M31 Technology Corporation (Taiwan stock code: 6643), a global Silicon Intellectual Property (IP) boutique, today announced that it has developed a diversified ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Ugandan HIV activists Barbara Kemigisa shows Antiretroviral (ARV) packagings and tablets in an art design encouraging people infected with HIV to use the ARVs and fight against stigmatisation ...

[DAVID GICHURU,Standard] People living with HIV/AIDS have urged the government to address concerns over a potential depletion of antiretroviral (ARV) drug stocks in the coming months. Nelson ...

The pharma group is paying $150 million upfront for rights to ARV-766, an oral androgen receptor (AR) protein degrader that generated positive results in a phase 1/2 trial reported at the last ...

– ARV-393 demonstrated significant single-agent activity in models of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type (also known as AITL) and transformed follicular lymphoma – – In ...